Pioglitazone may lower plaque inflammation in type 2 diabetes

10/12/2011 | MedPage Today (free registration)

Patients with carotid atherosclerosis and type 2 diabetes or impaired glucose tolerance who took 15 to 30 milligrams of pioglitazone for four months attained similar fasting plasma glucose levels as those who took glimepiride, but showed significant improvements in atherosclerotic plaque inflammation compared with the glimepiride-treated group, according to a study in JACC: Cardiovascular Imaging. Researchers found that patients who took pioglitazone had increased levels of high-density lipoprotein, which may have helped to suppress atherosclerotic plaque.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC